THOUGHT LEADERSHIP
What helps weight loss last beyond the first year?
A 24-month analysis offers new insight into weight-loss durability as GLP-1 use and treatment paths change
Dr. Christa-Marie Singleton, Senior Medical Director, Client Engagement and Virtual Care Outcomes Research
For plan sponsors investing in weight management, initial weight loss is only part of the equation. The harder question is whether progress lasts. Our 24-month analysis suggests progress can continue, even as treatment paths and GLP-1 use change over time.
The question matters because obesity treatment is rarely one-size-fits-all. Some people start and remain on medication, some begin later and others have no recorded use after their first year. Across those different paths, ongoing clinical and lifestyle support may play an important role in helping people sustain progress.
In a Teladoc Health analysis of nearly 23,000 people enrolled in the Weight Management or Diabetes Prevention programs, we examined outcomes over 24 months. The findings suggest that sustained weight loss is possible when people have access to ongoing clinical guidance, lifestyle support and tools that help reinforce healthy habits.
Notably, participants initially on a GLP-1 with no recorded GLP-1 use after the first year still maintained more than 9.4% weight loss at month 24.
That distinction matters when assessing program value. Initial weight loss is one measure, but durability is what creates lasting value.
Why changes in BMI risk category matter to plan sponsors
When discussing obesity treatment, weight loss often becomes the primary measure of success. While weight is important, it is only part of the story.
Body mass index (BMI) and obesity classifications give us perspective on an individual’s risk for conditions that commonly coexist with obesity. Our analysis found that the average BMI improved from 37 (which falls in Class 2 obesity) at enrollment to 34.7 (Class 1 obesity) after 24 months.
For benefits leaders, where in the BMI range weight loss occurs matters as much as the amount of weight loss. Healthcare spending rises with each obesity class and accelerates above a BMI of 35. A person does not have to reach a healthy BMI to demonstrate meaningful progress. Moving from a higher obesity category into a lower category can make a big impact on medical spending.
While our analysis didn’t directly measure claims savings, applying published annual healthcare-spending estimates to the observed weight-loss outcomes of the 22,962 members in our study projected substantial reductions in spending. We estimated $20.2 million reduction in annual medical spending across the study population, and the highest reduction in spending was most prominent among people who lost the largest percentage of weight and people with the highest BMI at enrollment.
What happens when recorded GLP-1 use changes?
One of the most important questions facing weight-loss durability is whether people can maintain progress as treatment evolves.
Among participants in our analysis, those with continuous recorded GLP-1 use experienced the greatest weight loss. However, participants with no recorded GLP-1 use after the first year also maintained substantial progress. This suggests that progress can occur across different treatment timelines when medication is paired with ongoing clinical and lifestyle support.
What was consistent for participants was ongoing participation in a Teladoc Health program focused on nutrition, physical activity, behavior change and habit formation.
As employers increasingly drop GLP-1 coverage for weight loss, with coverage among large employers falling from 72% in 2025 to 60% in 2026, clinical structure and lifestyle support are becoming more central to GLP-1 management. National survey data shows nine in 10 employers offer or are considering lifestyle programs, and use of GLP-1 management vendors rose from 11% to 28% in two years. Employers that drop coverage often leave members to pay on their own: 27% steer employees to direct-to-consumer platforms and 21% to HSA or FSA funds, outside both the plan’s data and clinical support (IFEBP).
For employers, this benefit gap design creates an opportunity to think about medication access and ongoing support together. Benefit approaches, such as employer contribution payment models, can help make GLP-1s more affordable while connecting people to the clinical and durable lifestyle support designed to help sustain progress over time.
How plan sponsors can evaluate weight-management value
Long-term weight management is often characterized by plateauing or weight regain. This real-world analysis, however, shows weight outcomes continued to improve between 12 and 24 months.
For plan sponsors, the implication is practical: Medication access matters, but medication alone is not the benefits strategy. A stronger measure of value is whether people have the support to remain engaged and sustain clinically meaningful progress as their needs and treatment paths change.
Weight management is not a one-time coverage decision. It is a long-term health journey. Benefits should be designed with that same long view.